These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. FDA tells drug and device makers to give balanced picture of risks in ads, labels. Kuehn BM JAMA; 2009 Jun; 301(24):2541. PubMed ID: 19549965 [No Abstract] [Full Text] [Related]
3. Trends in boxed warnings and withdrawals for novel therapeutic drugs, 1996 through 2012. Cheng CM; Shin J; Guglielmo BJ JAMA Intern Med; 2014 Oct; 174(10):1704-5. PubMed ID: 25127107 [No Abstract] [Full Text] [Related]
4. For U.S. drug companies' products sold in developing countries, labeling is often inadequate. Am J Hosp Pharm; 1994 Apr; 51(7):875-6. PubMed ID: 8017435 [No Abstract] [Full Text] [Related]
5. Problems Associated With Some Drug Formulations. Paul Y Indian Pediatr; 2019 Jun; 56(6):513-514. PubMed ID: 31278243 [No Abstract] [Full Text] [Related]
6. What's in a drug name? Wick JY J Am Pharm Assoc (2003); 2004; 44(1):12-4. PubMed ID: 14965147 [No Abstract] [Full Text] [Related]
7. The Food and Drug Administration's regulation of drug labeling, advertising, and promotion: looking back and looking ahead. Hayes TA Clin Pharmacol Ther; 1998 Jun; 63(6):607-16. PubMed ID: 9663174 [No Abstract] [Full Text] [Related]
9. FDA's Rx for keeping educational programs free of industry bias. Zappala FN Am J Health Syst Pharm; 1998 Dec; 55(23):2472, 2474. PubMed ID: 9853631 [No Abstract] [Full Text] [Related]
10. FDA transparency rules could hit small companies hardest. Allison M Nat Biotechnol; 2010 Aug; 28(8):767-8. PubMed ID: 20697386 [No Abstract] [Full Text] [Related]
12. "Safer, but not safe enough". Crombie HD Conn Med; 2006; 70(10):645. PubMed ID: 17190395 [No Abstract] [Full Text] [Related]
13. The INN crowd. Nat Biotechnol; 2013 Dec; 31(12):1055. PubMed ID: 24316620 [No Abstract] [Full Text] [Related]
14. Commentary: how the doctor can counter commercial bias in the dissemination of pharmacotherapeutic knowledge. Carpenter WT J Nerv Ment Dis; 2002 Sep; 190(9):593-6. PubMed ID: 12357092 [No Abstract] [Full Text] [Related]
15. New countermeasures considered as drug counterfeiting grows. Schubert C Nat Med; 2008 Jul; 14(7):700. PubMed ID: 18607355 [No Abstract] [Full Text] [Related]
16. [Quality control in the pharmaceutical industry]. Sloot HA Pharm Weekbl; 1968 Apr; 103(17):506-16. PubMed ID: 5665061 [No Abstract] [Full Text] [Related]
17. Drug promotion: stealth, wealth, and safety. Lancet; 1993 Jun; 341(8859):1507-8. PubMed ID: 8099382 [No Abstract] [Full Text] [Related]